Showing results (1151-1160 of 1,820) with videos related to

Sort By:
Pageof 182
Pulmonary Circulation|May 4, 2022
A second hit? Pulmonary arterial hypertension, BMPR2 mutation, and exposure to prescription amphetaminesHuzaifa A Jaliawala, Miloni Parmar, Katherine Summers, et al.
Pulmonary Circulation|May 4, 2022
Building a dedicated pediatric pulmonary hypertension program: A consensus statement from the pediatric pulmonary hypertension networkStephanie S Handler, Nidhy P Varghese, Erika B Rosenzweig, et al.
Pulmonary Circulation|May 4, 2022
Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertensionYuichi Tamura, Asuka Furukawa, Yudai Tamura, et al.
Pulmonary Circulation|May 4, 2022
CILP1 as a biomarker for right ventricular dysfunction in patients with ischemic cardiomyopathyStanislav Keranov, Leili Jafari, Saskia Haen, et al.
Pulmonary Circulation|May 4, 2022
Fecal matter transplant from Ace2 overexpressing mice counteracts chronic hypoxia-induced pulmonary hypertensionAline C Oliveira, Tao Yang, Jing Li, et al.
Pulmonary Circulation|May 4, 2022
Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin AmericaMauricio Orozco-Levi, Jorge Cáneva, Caio Fernandes, et al.
Pulmonary Circulation|May 4, 2022
Using health administrative data to identify patients with pulmonary hypertension: A single center, proof of concept validation study in Ontario, CanadaDon Thiwanka Wijeratne, Ahmad Housin, Katherine Lajkosz, et al.
Pulmonary Circulation|May 4, 2022
Crizotinib for ROS1-rearranged lung cancer and pulmonary tumor thrombotic microangiopathy under venoarterial extracorporeal membrane oxygenationDaisetsu Aoyama, Shigefumi Fukui, Haruhiko Hirata, et al.
Pulmonary Circulation|May 4, 2022
An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertensionMarc A Simon, Kate Hanrott, David C Budd, et al.
Pulmonary Circulation|July 14, 2022
Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activationEmmanouil Mavrogiannis, Quint A J Hagdorn, Venetia Bazioti, et al.
Pageof 182